TD Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

TD Asset Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,336	Closed	-$49K	–	1400
2016 Q2	$49K	Hold	5,336	–	–	﹤0.01%	1366
2016 Q1	$48K	Hold	5,336	–	–	﹤0.01%	1354
2015 Q4	$270K	Hold	5,336	–	–	﹤0.01%	1258
2015 Q3	$267K	Buy	5,336 +143	+3%	+$12.2K	﹤0.01%	1222
2015 Q2	$520K	Buy	+5,193	New	+$515K	﹤0.01%	1104

Other funds holding KALV

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Quadrant Glendale, California $18M AUM 24.2% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AFG

Albion Financial Group Salt Lake City, Utah $1.73B AUM 20.99% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TD Asset Management's KALV Position: Q3 2016 in Review

TD Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2016, closing a stake of 5,336 shares — an estimated $49K sold.

TD Asset Management first reported a position in KALV in Q2 2015 and held it in 5 quarters. The position peaked at $520K in Q2 2015. 21 funds tracked by Wall St. Rank hold KALV as of Q3 2016.

TD Asset Management reported no remaining KalVista Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
TD Asset Management sold 5,336 KalVista Pharmaceuticals shares in Q3 2016, an estimated $49K.
TD Asset Management first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 5 quarters.
TD Asset Management's KalVista Pharmaceuticals position peaked at $520K in Q2 2015.
21 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2016.

Based on TD Asset Management's 13F filing for Q3 2016, filed 2 Nov 2016.